“…Additionally, it has been shown that patients treated with rituximab earlier in the disease course may have better outcomes, enduring complete remission with no or minimal systemic therapy for 19 months (Lunardon et al, 2012[ 21 ]). Other studies also indicated that adjuvant rituximab therapy may hold promises in long-lasting treatment of severe recalcitrant PV with no or slight adverse drug-related events (Baum et al, 2013[ 4 ]; Behzad et al, 2012[ 5 ]; Cho et al, 2014[ 7 ]; Corral et al, 2013[ 9 ]; Craythorne et al, 2011[ 10 ]; El Tal et al, 2006[ 11 ]; Eming et al, 2008[ 12 ]).…”